Summit Partners Public Asset Management LLC Invests $3.19 Million in TransMedics Group, Inc. (NASDAQ:TMDX)

Summit Partners Public Asset Management LLC acquired a new position in TransMedics Group, Inc. (NASDAQ:TMDX) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 20,347 shares of the company’s stock, valued at approximately $3,194,000. Summit Partners Public Asset Management LLC owned approximately 0.06% of TransMedics Group at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Amalgamated Bank boosted its holdings in shares of TransMedics Group by 6.7% in the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after purchasing an additional 70 shares in the last quarter. Harbour Capital Advisors LLC boosted its holdings in TransMedics Group by 1.7% during the 3rd quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock valued at $760,000 after acquiring an additional 81 shares during the period. Signaturefd LLC boosted its holdings in TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after acquiring an additional 93 shares during the period. Arizona State Retirement System boosted its holdings in TransMedics Group by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock valued at $1,379,000 after acquiring an additional 186 shares during the period. Finally, Venturi Wealth Management LLC boosted its holdings in TransMedics Group by 33.7% during the 3rd quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock valued at $136,000 after acquiring an additional 219 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at TransMedics Group

In related news, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total transaction of $438,493.92. Following the completion of the transaction, the insider now owns 20,843 shares of the company’s stock, valued at $3,089,766.32. This trade represents a 12.43 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward M. Basile sold 6,750 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the transaction, the director now directly owns 732 shares of the company’s stock, valued at approximately $61,158.60. This trade represents a 90.22 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 26,958 shares of company stock valued at $3,470,328. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Stock Up 8.1 %

Shares of NASDAQ:TMDX opened at $87.11 on Friday. TransMedics Group, Inc. has a 52-week low of $67.77 and a 52-week high of $177.37. The firm has a market capitalization of $2.92 billion, a P/E ratio of 92.67 and a beta of 2.08. The stock has a 50 day moving average price of $113.26 and a 200-day moving average price of $136.45. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. During the same period in the prior year, the company posted ($0.12) EPS. The firm’s revenue was up 63.7% on a year-over-year basis. As a group, equities research analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on TMDX. Needham & Company LLC restated a “hold” rating and set a $109.00 target price on shares of TransMedics Group in a report on Friday, November 22nd. Stephens increased their target price on TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. JPMorgan Chase & Co. dropped their target price on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a report on Tuesday, October 29th. Oppenheimer dropped their target price on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a report on Tuesday, October 29th. Finally, Piper Sandler dropped their price objective on TransMedics Group from $180.00 to $110.00 and set an “overweight” rating for the company in a report on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.80.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.